|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Jonathan D. Alspaugh M.B.A.||Strategic Advisor||568,55k||S.O.||1983|
|Mr. James Paul Kastenmayer J.D., Ph.D.||Consultant||611,84k||S.O.||1972|
|Dr. Cameron Turtle DPHIL, Ph.D.||COO & Principal Executive Officer||S.O.||S.O.||1990|
|Mr. Scott L. Burrows||Chief Financial Officer||S.O.||S.O.||1977|
|Joey Perrone||Vice President of Finance & Investor Relations||S.O.||S.O.||S.O.|
|Ms. Heidy Abreu King-Jones J.D., L.L.M.||Chief Legal Officer & Corporate Secretary||S.O.||S.O.||1983|
|Dr. Kelly Boothe Ph.D.||Senior Director of Corporate Communications & Investor Relations||S.O.||S.O.||S.O.|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
L’ISS Governance QualityScore de Spyre Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..